341 related articles for article (PubMed ID: 25183241)
1. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
[TBL] [Abstract][Full Text] [Related]
2. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
Toubi E
Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
[TBL] [Abstract][Full Text] [Related]
3. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
[TBL] [Abstract][Full Text] [Related]
5. [Rituximab and hypogammaglobulinemia].
Fernández Romero DS; Torre MG; Larrauri BJ; Malbrán E; Juri MC; Malbrán A
Medicina (B Aires); 2015; 75(5):319-23. PubMed ID: 26502469
[TBL] [Abstract][Full Text] [Related]
6. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
[TBL] [Abstract][Full Text] [Related]
7. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T
Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
Casulo C; Maragulia J; Zelenetz AD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):106-11. PubMed ID: 23276889
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
Wade SD; Kyttaris VC
Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
[TBL] [Abstract][Full Text] [Related]
10. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era.
Chiou FK; Beath SV; Patel M; Gupte GL
Pediatr Transplant; 2019 Sep; 23(6):e13519. PubMed ID: 31209964
[TBL] [Abstract][Full Text] [Related]
11. [Absence of response to rituximab in patients with refractory primary immune thrombocytopenia].
Ma H; Wang Y; Sun L; Gong H
Zhonghua Yi Xue Za Zhi; 2014 Oct; 94(38):3011-3. PubMed ID: 25547706
[TBL] [Abstract][Full Text] [Related]
12. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
17. Secondary rituximab-associated versus primary immunodeficiencies: The enigmatic border.
Ottaviano G; Sgrulletti M; Moschese V
Eur J Immunol; 2022 Oct; 52(10):1572-1580. PubMed ID: 35892275
[TBL] [Abstract][Full Text] [Related]
18. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.
Audia S; Samson M; Guy J; Janikashvili N; Fraszczak J; Trad M; Ciudad M; Leguy V; Berthier S; Petrella T; Aho-Glélé S; Martin L; Maynadié M; Lorcerie B; Rat P; Cheynel N; Katsanis E; Larmonier N; Bonnotte B
Blood; 2011 Oct; 118(16):4394-400. PubMed ID: 21876120
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
[TBL] [Abstract][Full Text] [Related]
20. Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia.
Ottaviano G; Marinoni M; Graziani S; Sibson K; Barzaghi F; Bertolini P; Chini L; Corti P; Cancrini C; D'Alba I; Gabelli M; Gallo V; Giancotta C; Giordano P; Lassandro G; Martire B; Angarano R; Mastrodicasa E; Bava C; Miano M; Naviglio S; Verzegnassi F; Saracco P; Trizzino A; Biondi A; Pignata C; Moschese V
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):273-282. PubMed ID: 31377437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
